Browsing by Subject "apoptosis-inducing ligand"
Now showing items 1-9 of 9
-
Antianoikis effect of nuclear factor-κb through up-regulated expression of osteoprotegerin, bcl-2, and iap-1
(American Society for Biochemistry & Molecular Biology (ASBMB), 2006-01-05)Epithelial cells undergo a form of apoptosis termed anoikis when they lose extracellular attachments. We evaluated the role of transcription factor NF-kappa B in the regulation of anoikis susceptibility of intestinal ... -
Enhanced antitumor efficacy of a dr5-specific trail variant over recombinant human trail in a bioluminescent ovarian cancer xenograft model
(American Association for Cancer Research (AACR), 2009-03-10)Purpose: Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) is clinically evaluated as novel anticancer drug. rhTRAIL-DR5, a rhTRAIL variant that specifically binds to DR5 receptor, has ... -
Guiding the killer and bringing in accomplices: bispecific antibody treatment for malignant melanoma
(Elsevier BV, 2016-02-01)Discovery of oncogene and immune checkpoint targeting has transformed melanoma therapy in the last 5 years. However, treatment of primary or secondary drug-resistant melanoma remains a challenge. Agents designed to activate ... -
Mesenchymal stem cells expressing trail lead to tumour growth inhibition in an experimental lung cancer model
(Wiley-Blackwell, 2008-03-29)Lung cancer is a major public health problem in the western world, and gene therapy strategies to tackle this disease systemically are often impaired by inefficient delivery of the vector to the tumour tissue. Some of the ... -
Molecular pathways: toll-like receptors in the tumor microenvironment--poor prognosis or new therapeutic opportunity
(American Association for Cancer Research (AACR), 2012-12-27) -
The role of tumour necrosis factor related apoptosis-inducing ligand receptor signalling in tumour immune interactions
(NUI Galway, 2023-09-18)Death receptors are members of the tumor necrosis factor receptor (TNFR) superfamily, characterised by the presence of an intracellular alpha helical fold domain, called the death domain (DD) [1][2]. There are 8 death ... -
Targeting aml through dr4 with a novel variant of rhtrail
(Wiley-Blackwell, 2011-09-26)Despite progress in the treatment of acute myelogenous leukaemia (AML) the outcome often remains poor. Tumour necrosis factor related apoptosis-inducing ligand (TRAIL) is a promising therapeutic agent in many different ... -
The janus face of death receptor signaling during tumor immunoediting
(Frontiers Media SA, 2016-10-31)Cancer immune surveillance is essential for the inhibition of carcinogenesis. Malignantly transformed cells can be recognized by both the innate and adaptive immune systems through different mechanisms. Immune effector ... -
The trail-receptor-1: trail-receptor-3 and -4 ratio is a predictor for trail sensitivity of cancer cells
(Spandidos Publications, 2009-04-06)The tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in many cancer cells. However, a significant proportion of tumours are TRAIL-resistant erecting a major hurdle for a ...